ELIZABETH NAROUZ: Open Payments
NPI 1033687389 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$476 in 19 payments from 8 companies in 2025. Trend: 2023 $107 · 2024 $392 · 2025 $476
Food & beverage: $449Education: $27
| Company | Payments | Amount |
|---|---|---|
| Ardelyx, Inc. | 7 | $191 |
| Novo Nordisk Inc | 2 | $65 |
| AstraZeneca Pharmaceuticals LP | 2 | $56 |
| AKEBIA THERAPEUTICS INC | 2 | $51 |
| Novartis Pharmaceuticals Corporation | 2 | $50 |
| OPKO Pharmaceuticals, LLC | 1 | $26 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
| Travere Therapeutics, Inc. | 2 | $19 |
Products named: IBSRELA, FARXIGA, Vafseo, Fabhalta, Wegovy, Ozempic, RAYALDEE, JARDIANCE.
Industry payments across DC — which companies pay providers there.
